Health
Private equity reduces patient care while enriching investors, Senate report finds
A year-long bipartisan Congressional investigation into two private equity-backed U.S. hospital systems found that patient care deteriorated at both operations as their private equity owners reaped significant payouts on their investments in the systems. The findings reinforced academic research showing how private equity healthcare investments harm patients while enriching investors. The investigation was helmed by two senators […]
Read More
J&J says its lung cancer drug combination keeps people alive longer
Niels Wenstedt | Getty Images Johnson & Johnson on Tuesday said its lung cancer regimen keeps people alive for at least a year longer than AstraZeneca‘s Tagrisso, the go-to drug for a certain type of lung cancer. J&J in a statement said its drugs – Rybrevant and Lazcluze – showed a statistically significant and clinically […]
Read More
Hims & Hers donates $1 million to Trump’s inauguration fund
Hims & Hers Health has donated $1 million to President-elect Donald Trump’s inauguration fund, CNBC confirmed Tuesday. The company, which offers a range of direct-to-consumer treatments for conditions like weight loss, erectile dysfunction and hair loss, is the latest in a string of tech companies that have tried to curry favor with the incoming administration. […]
Read More
U.S. records its first human bird flu death
Test tubes are seen labelled “Bird Flu” words in this illustration taken, June 10, 2024. Dado Ruvic | Reuters The U.S. has recorded its first human death from bird flu, a grim milestone that comes as at least 66 cases have been recorded in the country. The patient, who was over 65 and had underlying medical […]
Read More
U.S. surgeon general calls for cancer risk warnings on alcohol labels
A customer drinks a glass of beer at the Saxton Pub in Austin, Texas, April 5, 2023. Brandon Bell | Getty Images The U.S. surgeon general issued a new advisory warning Friday about the link between alcohol consumption and increased cancer risk, and pushed for policy changes to help reduce the number of alcohol-related cancers. […]
Read More
These innovative biotech stocks have a good chance of breaking out in 2025
Trends may be shifting in favor of biotech stocks in 2025 after several years of poor performance, but it would still be wise to place your bets carefully on some of the most innovative names. “We’re still optimistic on the outlook for biotech,” said Stacey Sears, senior vice president and portfolio manager at Emerald Advisors, […]
Read More
Danaher had a disappointing 2024. Its path to success next year goes through Wall Street
Life sciences firm Danaher has certainly not been an easy stock to own this year. A wave of startups going public on Wall Street would go a long ways toward changing that. Year-to-date performance: down 0.1% Forward price-to-earnings multiple: 27.8 versus a five-year average of 28.8 Our rating: Buy-equivalent 1 Our price target: $305 a […]
Read More
FDA raises recall alert to highest level on Costco eggs over risk of severe illness or death due to salmonella
Eggs are displayed for sale inside a Costco store in Hawthorne, California, on January 26, 2023. Patrick T. Fallon | AFP | Getty Images Federal food regulators raised their alarm for recalled eggs sold from Costco stores over possible salmonella exposure, reclassifying the targeted product to their highest risk level. The FDA had previously announced on Nov. 27 that about […]
Read More
The ‘weight-loss trade’ has stalled. What it will take to revive investor interest
Anyone who’s been on a diet can likely relate: Those first lost pounds are met with a sense of euphoria. The voice inside one’s head screams: “I’ve got this!” But then, it inevitably becomes a slog. The initial novelty wears off, and the real work begins. Investors may see a parallel to the initial elation […]
Read More
Eli Lilly looks to extend its winning streak over the broader market to 6 years
Eli Lilly has outperformed the S & P 500 for five straight years as Wall Street woke up to its massive opportunity in obesity drugs. Six in a row is not out of the question. Year-to-date performance: Up 33.7% Forward price-to-earnings ratio: 34.3 versus five-year average of 34.5 Our rating: Buy-equivalent 1 Our price target: […]
Read More